Tratamiento actual de la hepatitis C en Colombia
DOI:
https://doi.org/10.52784/27112330.119Palabras clave:
hepatitis C, tratamiento, genotipo, antivirales, respuesta virológica sostenida.Resumen
La infección por el virus de hepatitis C (VHC) es una epidemia global que afecta a 71 millones de personas. El diagnóstico inicial se hace mediante la detección de anticuerpos contra el VHC, que luego requiere una prueba confirmatoria molecular, debido a que la determinación de anticuerpos no diferencia los individuos que tienen una infección activa, de aquellos con una infección resuelta y sin viremia. El objetivo del tratamiento de la infección crónica por VHC es curar la enfermedad, lo que se determina cuando se logra una respuesta viral sostenida; es decir, cuando no se detecta carga viral 12 semanas o más después de terminada la terapia. Para un tratamiento óptimo de la infección y alcanzar la curación, se recomienda evaluar previamente de manera no invasiva el estadio de fibrosis, y garantizar la adherencia durante todo el tiempo de tratamiento. En la presente revisión se incluyen las recomendaciones para el tratamiento de la infección crónica por VHC, según el genotipo viral, basadas en los medicamentos disponibles en nuestro medio y en los que próximamente estarán llegando al país.
Descargas
Referencias bibliográficas
World Health Organization (WHO). Eliminate hepatitis: WHO. Ginebra, Suiza: World Health Organization; 2017. Acceso 20 de marzo de 2020. Disponible en https://www.who.int/news-room/detail/27-07-2017-eliminate-hepatitis-who.
Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 2019;394:1451-1466. https://doi.org/10.1016/s0140-6736(19)32320-7.
Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-176. https://doi.org/10.1016/S2468-1253(16)30181-9.
World Health Organization (WHO). Hepatitis C: fact sheets. Ginebra, Suiza: World Health Organization; 2019. Acceso 15 de marzo de 2020. Disponible en https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, et al. Prevalence of hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. https://doi.org/10.1002/jcla.22876.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-171. https://doi.org/10.1016/S0140-6736(14)61682-2.
Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology 2019;69:1020-1031. https://doi.org/10.1002/hep.30297.
Mohd-Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342. https://doi.org/10.1002/hep.26141.
Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun 2019;20:436-446. https://doi.org/10.1038/s41435-019-0066-z.
Hoyos A, Vanegas N, Páez E. Epidemiología de la hepatitis C en Colombia. Acta Med Colomb 2002;27:209-217.
Arroyave JC, Álvarez C, Correa A G, Balcázar M N, Arbeláez M MP, Navas N MC. Infección por el virus de la hepatitis C en individuos transfundidos antes de 1994 en Antioquia, Colombia. Rev Col Gastroenterol 2014;29:383-389.
Sepúlveda-Arias JC, Isaza C, Vélez JP. Hepatitis B and C prevalence among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Pereira, Colombia. J Infect Dev Ctries 2014;8:1228-1230. https://doi.org/10.3855/jidc.4525.
Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges. Int J Med Sci 2020;17:892-902. https://doi.org/10.7150/ijms.43079.
Daniel KE, Saeian K, Rizvi S. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat 2020;27:195-204. https://doi.org/10.1111/jvh.13218.
Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, et al. Identification of a novel hepatitis C virus genotype from Punjab, India: Expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 2018;218:1722-1729. https://doi.org/10.1093/infdis/jiy401.
Tsukiyama-Kohara K, Kohara M. Hepatitis C virus: Viral quasispecies and genotypes. Int J Mol Sci 2017;19:23. https://doi.org/10.3390/ijms19010023.
Santos Ó, Gómez A, Vizcaíno V, Casas MC, Ramírez MdP, Olaya P. Genotipos circulantes del virus de la hepatitis C en Colombia. Biomédica 2017;37:22-27. https://doi.org/10.7705/biomedica.v37i1.3173.
Hutin Y, Bulterys M, Hirnschall GO. How far are we from viral hepatitis elimination service coverage targets? J Int AIDS Soc 2018;21:e25050. https://doi.org/10.1002/jia2.25050.
Centers for Disease Control and Prevention (CDC). Testing recommendations for hepatitis C virus infection. Atlanta, Georgia: CDC; 2020. Acceso 28 de febrero de 2020. Disponible en https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm.
Fourati S, Feld JJ, Chevaliez S, Luhmann N. Approaches for simplified HCV diagnostic algorithms. J Int AIDS Soc 2018;21:e25058. https://doi.org/10.1002/jia2.25058.
Chevaliez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti Infect Ther 2019;17:341-347. https://doi.org/10.1080/14787210.2019.1604221.
Centers for Disease Control and Prevention (CDC). Testing for HCV infection: An update of guidance for clinicians and laboratorians weekly. Morbidity and Mortality Weekly Report (MMWR). Atlanta, Georgia: CDC; 2013. Acceso 11 de marzo de 2020. Disponible en https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6218a5.htm.
Arca-Lafuente S, Martínez-Román P, Mate-Cano I, Madrid R, Briz V. Nanotechnology: A reality for diagnosis of HCV infectious disease. J Infect 2020;80:8-15. https://doi.org/10.1016/j.jinf.2019.09.010.
Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014;20:3431-3442. https://doi.org/10.3748/wjg.v20.i13.3431.
American Association for the Study of Liver Diseases (AASLD). Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy. Virginia, USA: 2019. Acceso 18 de marzo de 2020. Disponible en https://www.hcvguidelines.org/evaluate/monitoring.
D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-368. https://doi.org/10.5812/hepatmon.6095.
D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012;56:532-543. https://doi.org/10.1002/hep.25606.
Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-1192. https://doi.org/10.1053/j.gastro.2014.03.003.
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016;65:524-531. https://doi.org/10.1016/j.jhep.2016.05.010.
Wedemeyer H, Berg T, Flamm SL, Foster GR, Craxi A, Larrey D, et al. P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis. J Hepatol 2015;62:S637-S638. https://doi.org/10.1016/S0168-8278(15)31011-4.
World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Ginebra, Suiza; World Health Organization. 2018. p. 108. ISBN 978-92-4-155034-5.
Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2018;183:118-126. https://doi.org/10.1016/j.pharmthera.2017.10.009.
Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology 2020;71:686-721. https://doi.org/10.1002/hep.31060.
Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461-511. https://doi.org/10.1016/j.jhep.2018.03.026.
Varón A, Santos L, Tapias M, Cáez C, Marín JI, Santos O, et al. Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents. Medicina (B Aires) 2019;79:29-36.
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med 2015;163:1-13. https://doi.org/10.7326/m15-0785.
Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017;152:164-175.e4. https://doi.org/10.1053/j.gastro.2016.09.045.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354-369. https://doi.org/10.1056/NEJMoa1702417.
Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-1068. https://doi.org/10.1016/s1473-3099(17)30496-6.
Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-2607. https://doi.org/10.1056/NEJMoa1512610.
Tsai N, Bacon B, Curry M, Dieterich D, Flamm S, Kowdley K, et al. Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network. J Hepatol 2017;66:S726. https://doi.org/10.1016/S0168-8278(17)31938-4.
Khalili M, Welzel T, Lim J, Lutchman GA, Nelson D, Borg B, et al. Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1–6: results of the HCV-TARGET Study. J Hepatol 2017;66:S716-S717. https://doi.org/10.1016/S0168-8278(17)31916-5.
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017;67:263-271. https://doi.org/10.1016/j.jhep.2017.03.039.
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-2617. https://doi.org/10.1056/NEJMoa1512612.
Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 2017;153:113-122. https://doi.org/10.1053/j.gastro.2017.03.047.
Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, Pol S, et al. ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis. J Hepatol 2017;66:S33. https://doi.org/10.1016/S0168-8278(17)30326-4.
Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int 2018;38:1583-1591. https://doi.org/10.1111/liv.13727.
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018;16:417-426. https://doi.org/10.1016/j.cgh.2017.09.027.
Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int 2018;38:443-450. https://doi.org/10.1111/liv.13534.
Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol 2019;4:45-51. https://doi.org/10.1016/s2468-1253(18)30341-8.
Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376:2134-2146. https://doi.org/10.1056/NEJMoa1613512.
Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology 2018;67:1253-1260. https://doi.org/10.1002/hep.29671.
Ministerio de Salud y Protección Social. Instituto de Evaluación tecnológica en Salud. Guía de práctica clínica para la tamización, diagnóstico y tratamiento de personas con infección por el virus de la hepatitis C. Bogotá: Ministerio de Salud y Protección Social; 2018. p. 311. Acceso 15 de marzo de 2020. Disponible en http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_hepatitis/gpc_hepatitis_c_completa.aspx.
Ministerio de Salud y Protección Social. Ministerio de Hacienda y Crédito Público. Informe de seguimiento de casos con hepatitis C crónica en el marco de la estrategia de negociación y compra centralizada de medicamentos. Bogotá: Ministerio de Salud y Protección Social; 2019. p. 25. Acceso 25 de febrero de 2020. Disponible en https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/042019-ca-c3350-informe-hepatitisc.pdf.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
